Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies

Transplantation

Volumn 75, Issue 10, 2003, Pages 1748-1751

  Spitzer, Thomas R ^a   McAfee, Steven L ^a   Dey, Bimalangshu R ^a   Colby, Christine ^a   Hope, James ^b   Grossberg, Howard ^b   Preffer, Frederic ^a   Shaffer, Juanita ^a   Alexander, Stephen I ^a   Sachs, David H ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BioTransplant Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; SIPLIZUMAB;

ADULT; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CHIMERA; CLINICAL ARTICLE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; BONE MARROW; BONE MARROW TRANSPLANTATION; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HAPLOIDY; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MIDDLE AGED; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 20244388936     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000064211.23536.AD     Document Type: Article

References (10)

1. Henslee-Downey PJ. Mismatched bone marrow transplantation. Curr Opin Oncol 1995; 2: 115-121.
2. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493-507.
3. Pelot MR, Pearson DA, Swenson K, et al. Lymphohematopoietic graft-vshost reactions can be induced without graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 133-144.
4. Mapara MY, Pelot M, Zhao G, et al. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant 2001; 7: 646-655.
5. Mapara MY, Kim YM, Wang SP, et al. Donor lymphocyte infusions (DLI) mediate superior graft-versus-leukemia (GVL) effects in mixed compared to fully allogeneic chimeras: a critical role for host antigenpresenting cells. Blood 2002; 100: 1903-1909.
6. Sykes M, Preffer F, Saidman SL, et al. Mixed Lymphohematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 1998; 353: 1755-1759.
7. Branco L, Barren P, Mao SY, et al. Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 1999; 68: 1588-1596.
8. Adkins DE, Ratanatharathom V, Dingivan C. A phase-I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-CD2 monoclonal antibody in the initial treatment of at least grade II acute graft-versus-host disease. Blood 2000; 96: 2050a.
9. Spitzer TR, McAfee S, Sackstein R, et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Bone Marrow 2000; 6: 309-320.
10. Spitzer, TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.